Table 9. Frequency of late toxicities (CTCAE 3.0) in patients with more than one year of follow-up (n = 810).
| Toxicity | Any Grade | Grade 3–4 | Any Grade: CCRT vs. Non-CCRT | p value | Grade 3–4: CCRT vs. Non-CCRT | p value | Any Grade: Total dose of cisplatin ≥ 300 mg/m2vs. < 300 mg/m2 | p value | Grade 3–4: Total dose of cisplatin ≥ 300 mg/m2vs. < 300 mg/m2 | p value |
|---|---|---|---|---|---|---|---|---|---|---|
| Xerostomia | 330 (40.7%) | 32 (4.0%) | 46.4% vs. 36.3% | 0.003* | 5.6% vs. 2.7% | 0.034* | 44.1% vs. 37.5% | 0.035* | 5.0% vs. 2.9% | 0.127 |
| Hearing impairment | 175 (21.6%) | 27 (3.3%) | 24.0% vs. 19.7% | 0.132 | 3.9% vs. 2.9% | 0.659 | 25.1% vs. 18.2% | 0.013* | 4.8% vs. 1.9% | 0.026* |
| Hearing loss | 105 (13.0%) | 14 (1.7%) | 14.8% vs. 11.5% | 0.170 | 2.0% vs. 1.5% | 0.261 | 15.5% vs. 10.5% | 0.026* | 2.8% vs. 0.7% | 0.027* |
| Tinnitus | 77 (9.5%) | 1 (0.1%) | 10.1% vs. 8.8% | 0.467 | 0.3% vs. 0% | 0.788 | 11.5% vs. 7.5% | 0.052 | 0.3% vs. 0% | 0.493 |
| Otitis media | 26 (3.2%) | 14 (1.7%) | 4.5% vs. 2.2% | 0.074 | 2.0% vs. 1.5% | 0.659 | 3.3% vs.3.2% | 0.929 | 2.0% vs. 1.5% | 0.599 |
| Cranial nerve injury | 22 (2.7%) | 19 (2.3%) | 3.6% vs. 2.2% | 0.152 | 3.1% vs. 1.8% | 0.224 | 3.8% vs. 1.7% | 0.073 | 3.0% vs. 1.7% | 0.220 |
| Temporal lobe necrosis | 45 (5.6%) | 7 (0.9%) | 6.1% vs. 5.1% | 0.519 | 0.8% vs. 0.8% | 0.943 | 6.0% vs. 5.1% | 0.562 | 1.0% vs. 0.7% | 0.722 |
| Trismus | 11 (1.4%) | 2 (0.2%) | 2.8% vs. 0.2% | 0.001* | 0.6% vs. 0% | 0.195 | 1.8% vs. 1.0% | 0.299 | 0.5% vs. 0% | 0.242 |
| Secondary malignancy | 6 (0.7%) | 6 (0.7%) | 1.4% vs. 0.2% | 0.093 | 1.4% vs. 0.2% | 0.093 | 1.3% vs. 0.2% | 0.118 | 1.2% vs. 0.2% | 0.118 |
Abbreviation: CCRT. = concurrent chemotherapy.
*
indicated p < 0.05.